Zamtocabtagene autoleucel reduced the risk of an event against R-GemOx in transplant-ineligible second-line large B-cell lymphoma, with serious …
Zamtocabtagene autoleucel reduced the risk of an event against R-GemOx in transplant-ineligible second-line large B-cell lymphoma, with serious …
Pozdeutinurad produced significant and durable urate lowering in uncontrolled gout, with treatment-emergent adverse-event rates close to placebo
Interim Phase 1b/2a results showed durable swallowing improvements at the low dose and larger three-month gains at the …
New PMN310 data presented in London show measurable drops in cerebrospinal fluid amyloid-beta oligomers at three and 29 …
Efanesoctocog alfa’s extended half-life offers Australian patients a substantially reduced infusion burden compared with existing factor VIII replacement …
Gene-edited cell therapy exagamglogene autotemcel extends to pediatric patients as young as two, based on trial data showing …
The approval of efanesoctocog alfa brings an extended half-life factor VIII replacement to the Australian market, arriving as …
The donor-derived cell therapy is designed to be infused alongside a stem cell transplant, aiming to reduce a …
The bispecific antibody paired with lenalidomide showed a statistically significant improvement over standard care in patients with relapsed …
Amtagvi becomes the first tumour-infiltrating lymphocyte therapy approved in Australia for advanced melanoma, entering a market with the …
Already a subscriber? Log in